Andrea Kerkhoff

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Paul J. Bröckelmann, Helen Goergen, Ulrich Keller et al. · JAMA Oncology · 2020 · 169 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann, Annette Plütschow, Carsten Kobe et al. · The Lancet Oncology · 2021 · 168 citations

Medicine, Oncology, Radiology +13

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · The Lancet · 2024 · 136 citations · Full text

Medicine, Hematology, Oncology +10

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Beate Schultheis, Dirk Reuter, M. Ebert et al. · Annals of Oncology · 2017 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer et al. · Blood · 2016 · 115 citations · Full text

Medicine, Geriatric Medicine, Oncology +13